Considerations in the management of elderly patients with chronic myeloid leukemia.

  • Karen Seiter
  • Published 2012 in Clinical lymphoma, myeloma & leukemia


The introduction of tyrosine kinase inhibitor (TKI) treatment has provided a remarkable survival benefit such that it is possible that patients with chronic myeloid leukemia might live a normal life span. Coupled with a median age of onset of 65 years, many patients will be elderly at diagnosis or can expect to attain elderly status during their course of… (More)
DOI: 10.1016/j.clml.2011.10.001


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics